Antisoma's AS1404 boosts survival in Ph II NSCLC trial
UK-based Antisoma, a specialist in the development of oncology drugs, says that data from a Phase II trial of AS1404 in non-small cell lung cancer shows that the agent confers a substantial survival benefit.
The company explained that patients who received AS1404, as well as standard chemotherapy, had a median survival time of 14.0 months versus 8.8 months in those who were treated with chemotherapy alone. In addition, those who received the drug had a 27% lower risk of dying than subjects in the chemotherapy arm.
Antisoma said that the agent is also in trials as a treatment for prostate and ovarian cancer, and added that it is in talks with a number of companies regarding potential out-licensing deals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze